Women and HIV

MEDICAL ADVOCATES WOMEN AND HIV RESOURCE CENTER
		HIV Clinical Management
		General Reports ART Drugs HAART Diagnostics/Monitoring

Women abd HIV Main Page

Main New and Noteworthy

Home Page

Last Update: March 28, 2018
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
Additional HIV Management Reports are Indexed under Applicable National Web Pages

General Reports

Journal Papers, Abstracts, and Commentaries

Associations Among Trajectories of Sleep Disturbance, Depressive Symptomology and 24-Hour Urinary Cortisol in HIV+ Women Following a Stress Management Intervention.
McIntosh R, Antoni M, Seay J,et al
Behav Sleep Med. 2018 Feb 20:1-16.
Abstrac

Effects of depot-medroxyprogesterone acetate on the immune microenvironment of the human cervix and endometrium: implications for HIV susceptibility.
Smith-McCune KK, Hilton JF, et al
Mucosal Immunol. 2017 Jan 4.
Abstract

The successful use of lipectomy in the management of airway obstruction in a woman with HIV-associated lipodystrophy.
Tsui E, Bogdasarian R, Blomain E.
MJ Case Rep. 2015 Feb 18;201
Abstract

Women, Aging, and HIV: Clinical Issues and Management Strategies.
Womack JA, Brandt CA, Justice AC.
J Nurse Pract. 2014 Jun 1;10(6):409-416.
Abstract

FULL-TEXT PDF COMMENTARY
Asking the right questions: developing evidence-based strategies for treating HIV
in women and children
l Karim QA, Banegura A, Cahn P, et al
BMC Public Health 2011, 11:388
Paper

ART Drugs

General Reports

Journal Papers, Abstracts, and Commentaries

Women in HIV trials: improving adherence and outcomes.
Cohn SE
.Lancet HIV. 2017 Jul 17
Abstract

Food insecurity, sexual risk behavior, and adherence to antiretroviral therapy among women living with HIV: A systematic review.
Chop E, Duggaraju A, Flignor A, et al
Health Care Women Int. 2017 Jun 6:0
Abstract

Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.
Squires K, Kityo C, Hodder S, Johnson M, et al
Lancet HIV. 2016 Sep;3(9):e410-20.
Abstract

Menstrual cycle phase and single tablet antiretroviral medication adherence in women with HIV.
Hessol NA, Holman S, Minkoff H, et al.
AIDS Care. 2015 Aug 14:1-11
Abstract

Analysis of endoplasmic reticulum stress in placentas of HIV-infected women treated with protease inhibitors.
Brüning A, Kimmich T, Brem GJ, et al
Reprod Toxicol. 2014 Dec;50:122-8.
Abstract

What do we know about antiretroviral treatment of HIV in women?
Monforte Ad, Anderson J, Olczak A.
Antivir Ther. 2013;18 Suppl 2:27-34.
Abstract

Abacavir

Journal Papers, Abstracts, and Commentaries

Abacavir alters the transcription of inflammatory cytokines in virologically suppressed,
HIV-infected women.
Macleod IJ, Rowley CF, Lockman S, et al
J Int AIDS Soc. 2012 Jul 10;15(2):1-8.
Abstract

Atazanavir

Journal Papers, Abstracts, and Commentaries

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Orrell C, Hagins DP, Belonosova E, et al
Lancet HIV. 2017 Jul 17.
Abstract

Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen.
Meditz AL, Palmer C, Predhomme J,et al
AIDS Res Hum Retroviruses. 2015 Jun 10.
Abstract

Simultaneous plasma and genital pharmacokinetics and pharmacodynamics of atazanavir and efavirenz in HIV-infected women starting therapy.
Neely M, Louie S, Xu J, et al
J Clin Pharmacol. 2015 Feb 12
Abstract

Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy.
DuBois BN, Atrio J, Stanczyk FZ, Cherala G.
Contraception. 2014 Aug 30.
Abstract

A systematic review of the use of atazanavir in women infected with HIV type-1.
Johnson M, Walmsley S, Haberl A.
Antivir Ther. 2014 Jan 31.
Abstract

Dapivirine

Journal Papers, Abstracts, and Commentaries

Dual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polyester-based swabs via liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysis.
Parsons TL, Emory JF, Seserko LA, et al J
Pharm Biomed Anal. 2014 Sep;98:407-16.
Abstract

Dolutegravir

Journal Papers, Abstracts, and Commentaries

Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV negative women.
Adams JL, Patterson KB, Prince HM, et al
Antivir Ther. 2013 Jul 31.
Abstract

Efavirenz

Journal Papers, Abstracts, and Commentaries

Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines.
Patel RC, Morroni C, Scarsi KK, et al
lJ Int AIDS Soc. 2017 May 11;20(1):1
Abstract.

Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels
when co-administered with combined oral contraceptives.
Landolt NK, Phanuphak N, Ubolyam S, et al
J Acquir Immune Defic Syndr. 2012 Nov 26
Abstract

FULL-TEXT ARTICLE
Efavirenz conceptions and regimen management in a prospective cohort of women on antiretroviral therapy.
Schwartz S, Taha TE, Venter WD, et al
Infect Dis Obstet Gynecol. 2012;2012:723096
Paper
.
Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex,
and a baseline CD4 cell count greater than 250 cells/mul
Manfredi R, Calza L.
AIDS. 2006 Nov 14;20(17):2233-2236.
Abstract

Etravirine

Journal Papers, Abstracts, and Commentaries
	Etravirine Concentrations in the Cervico-Vaginal Compartment in HIV-1 infected Women receiving Etravirine-containing antiretroviral therapy: DIVA 02 study. Clavel C, Peytavin G, Tubiana R, et al Antimicrob Agents Chemother. 2012 Apr 23. Abstract

Lopinavir/Ritonavir

Journal Papers, Abstracts, and Commentaries

Depot Medroxyprogesterone Acetate (DMPA) in Combination with Twice Daily Lopinavir/Ritonavir-Based Regimen in HIV-Infected Women:
Effective Contraception, Lack of Clinically Significant Interactions, with Good Safety and Tolerability: Results of ACTG 5283.
Luque AE, Cohn SE, Park JG, et al
Antimicrob Agents Chemother. 2015 Jan 26.
Abstract

Lopinavir/ritonavir in human immunodeficiency virus-infected women.
Téllez MJ.
Enferm Infecc Microbiol Clin. 2014 Nov;32 Suppl 3:22-5.
Abstract

Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women.
Vieira CS, Bahamondes MV, de Souza RM, et al
J Acquir Immune Defic Syndr. 2014 May 4.
Abstract

Cost-effectiveness of atazanavir+ritonavir (ATV+RTV) vs. lopinavir/ritonavir (LPV/r) in women of childbearing age in the United Kingdom.
Simpson K, Kirbach S, Van de Steen O, Gooch K.
J Int AIDS Soc. 2012 Nov 11;15(6):18385
Abstract

Meta-Analysis of the Safety, Tolerability, and Efficacy of Lopinavir/Ritonavir-Containing Antiretroviral Therapy in HIV-1-Infected Women.
Hermes A, Squires K, Fredrick L, et al
HIV Clin Trials. 2012 Nov-Dec;13(6):308-23.
Abstract

Maraviroc

Journal Papers, Abstracts, and Commentaries

Dual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polyester-based swabs via liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysis.
Parsons TL, Emory JF, Seserko LA, et al
J Pharm Biomed Anal. 2014 Sep;98:407-16.
Abstract

Nevirapine

Journal Papers, Abstracts, and Commentaries

FULL-TEXT ARTICLE
Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study.
Oluka MN, Okalebo FA, Guantai AN, et al
AIDS Res Ther. 2015 Apr 15;12:10.
Paper

Nevirapine (NVP) pharmacokinetics (PK) and risk of rash and hepatitis among HIV-infected Sub-Saharan
African Women.
Dong BJ, Zheng Y, Hughes MD, et al
AIDS. 2012 Feb 1
Abstract

Raltegravir

Journal Papers, Abstracts, and Commentaries

Effect of HIV-infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract.
Cottrell ML, Patterson KB, Prince HM, et al
Antivir Ther. 2015 Jun 3.
Abstract

Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.
Lake J, McComsey G, Hulgan T, et al
HIV Med. 2014 Feb 10.
Abstract

Raltegravir Concentrations in the Genital Tract of HIV-1 infected Women Treated with a
raltegravir containing Regimen : DIVA 01 study
Clavel C, Peytavin G, Tubiana R, et al
Antimicrob Agents Chemother. 2011 Mar 28.
Abstract

Saquinavir

Journal Papers, Abstracts, and Commentaries

Pharmacokinetic Study of Saquinavir 500 mg Plus Ritonavir (1000/100 mg Twice a Day) in
HIV-Positive Pregnant Women.
Martinez-Rebollar M, Lonca M, Perez I, et al
Ther Drug Monit. 2011 Dec;33(6):772-7
Abstract

Tenofovir

Journal Papers, Abstracts, and Commentaries

FULL-TEXT ARTICLE
Influence of Chitosan Swelling Behaviour on Controlled Release of Tenofovir from Mucoadhesive Vaginal Systems for Prevention of Sexual Transmission of HIV.
Notario-Pérez F, Martín-Illana A, Cazorla-Luna R, et al
Mar Drugs. 2017 Feb 21;15(2). pii: E50
Paper

An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate.
Baum MM, Butkyavichene I, Churchman SA, et al
Int J Pharm. 2015 Sep 16.
Abstract

Vaginal deployment and tenofovir delivery by microbicide gels.
Gao Y, Yuan A, Chuchuen O, et al
Drug Deliv Transl Res. 2015 Apr 15.
Abstract

Effects of Tenofovir on Cytokines and Nucleotidases in HIV-1 Target Cells and the Mucosal Tissue Environment in the Female Reproductive Tract.
Biswas N, Rodriguez-Garcia M, Shen Z, et al
Antimicrob Agents Chemother. 2014 Aug 18.
Abstract

FULL-TEXT ARTICLE
Sex Hormones Regulate Tenofovir-Diphosphate in Female Reproductive Tract Cells in Culture.
Shen Z, Fahey JV, Bodwell JE, et al
PLoS One. 2014 Jun 30;9(6):e100863.
Paper

FULL-TEXT ARTICLE
Cervical Cancer Precursors and Hormonal Contraceptive Use in HIV-Positive Women: Application of a Causal Model and Semi-Parametric Estimation Methods.
Leslie HH, Karasek DA, Harris LF, et al
PLoS One. 2014 Jun 30;9(6):e101090.
Paper

Sensitive Tenofovir Resistance Screening of HIV-1 from the Genital and Blood Compartments of Women with Breakthrough Infections
in the CAPRISA 004 Tenofovir Gel Trial.
Wei X, Hunt G, Karim SS, et al
J Infect Dis. 2014 Jan 16
Abstract

FULL-TEXT ARTICLE
Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events.
Gervasoni C, Meraviglia P, Landonio S,et al
PLoS One. 2013 Dec 2;8(12):e80242
Paper

Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics
in a large cohort of HIV-infected women.
Baxi SM, Greenblatt RM, Bacchetti P, et al
AIDS. 2013 Nov 23.
Abstract

An Evaluation of Polycaprolactone Matrices for Vaginal Delivery of the Antiviral, Tenofovir, in Preventing Heterosexual Transmission of HIV.
Dang NT, Sivakumaran H, Harrich D, Coombes AG.
J Pharm Sci. 2013 Jul 31
Abstract

Tenofovir accelerates bone mass loss of the lumbar spine in the first years of menopause in HIV-infected women.
Garlassi E, Zona S, Vescini F, et al
J Int AIDS Soc. 2012 Nov 11;15(6):18317.
Abstract

Tenofovir use and urinary biomarkers among HIV-infected women in the Women's Interagency HIV Study (WIHS).
Oboho I, Abraham A, Benning L, et al
J Acquir Immune Defic Syndr. 2012 Dec 18.
Abstract

Simultaneous Delivery of Tenofovir and Acyclovir via an Intravaginal Ring.
Moss JA, Malone AM, Smith TJ, et al
Antimicrob Agents Chemother. 2011 Nov 28.
alafenamide t

Tenofovir/Emtricitabine

Journal Papers, Abstracts, and Commentaries

Tenofovir Alafenamide

Journal Papers, Abstracts, and Commentaries

Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.
Mandal S, Prathipati PK, Kang G, et al
AIDS. 2017 Feb 20;31(4):469-476.
Abstract

HAART/ART
Additional HAART Reports are Indexed under Applicable National Web Pages

General Reports

Journal Papers, Abstracts, and Commentaries

Pharmacogenetic Associations with ADME Variants and Virologic Response to an Initial HAART Regimen in HIV-Infected Women.
Pearce CL, Stram D, Wiensch A,, et al
Int J HIV AIDS Res. 2017;4(3):154-160.
Abstract

Factors Supporting and Inhibiting Adherence to HIV Medication Regimen in Women: A Qualitative Analysis of Patient Interviews.
Fagbami O, Oluwasanjo A, Fitzpatrick C, et al
Open AIDS J. 2015 May 15;9:45-50.
Abstract

Optimizing antiretroviral therapy for women living with HIV.
Greig JM, Anderson J.
Curr Opin Infect Dis. 2014 Feb;27(1):46-52
Abstract

Increase in Single Tablet Regimen Use and Associated Improvements in Adherence -Related Outcomes in HIV-Infected Women
Hanna DB, Hessol NA, Golub ET, et al
J Acquir Immune Defic Syndr. 2013 Dec 8
Abstract

Optimizing antiretroviral therapy for women living with HIV.
Greig JM, Anderson
J.Curr Opin Infect Dis. 2013 Dec 7
Abstract

Relationship Between Poor Physical Function, Inflammatory Markers, and Comorbidities in HIV-Infected Women on Antiretroviral Therapy.
Baranoski AS, Harris A, Michaels D,
J Womens Health (Larchmt). 2013 Nov 12.
Abstract

Effects of pill burden on discontinuation of the initial HAART regimen in minority female patients prescribed 1 pill/day versus any other pill burden.
Hill S, Kavookjian J, Qian J, et al
AIDS Care. 2013 Oct 10.
Abstract

Improvements in virological control among women conceiving on cART in Western Europe.
Bailey H, Townsend CL, Cortina-Borja M, et al
AIDS. 2013 Jun 3
Abstract

FULL-TEXT PDF ARTICLE
Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study.
Loutfy MR, Walmsley SL, Klein MB, et al
BMC Infect Dis. 2013 Jun 3;13(1):256
Paper

Associations of cardiovascular variables and HAART with cognition in middle-aged HIV-infected
and uninfected women.
Crystal HA, Weedon J, Holman S, et al
J Neurovirol. 2011 Oct 18
Abstract

Lack of effect of compartmentalized drug resistance mutations on HIV-1 pol divergence
in antiretroviral-experienced women.
Kelley CF, Sullivan ST, Lennox JL, et al
AIDS. 2010 Apr 12.
Abstract

Adherence

Journal Papers, Abstracts, and Commentaries

Barriers to HIV Medication Adherence: Examining Distinct Anxiety and Depression Symptoms among Women Living with HIV Who Experienced Childhood Sexual Abuse.
Willie TC, Overstreet NM, Sullivan TP, et al
Behav Med. 2015 May 26:0.
Abstract

An investigation of the possible interaction between the use of Vitamin C and highly active antiretroviral therapy (HAART) adherence and effectiveness in treated HIV+ women.
Merenstein D, Wang C, Gandhi M, et al
Complement Ther Med. 2012 Aug;20(4):222-7
Abstract
Recent Trauma is Associated with Antiretroviral Failure and HIV Transmission Risk Behavior Among
HIV-Positive Women and Female-Identified Transgenders.
Machtinger EL, Haberer JE, Wilson TC, Weiss DS.
AIDS Behav. 2012 Mar 17.
Abstract

Resistance

Journal Papers, Abstracts, and Commentaries

HIV-1 Drug Resistance in Variants from the Female Genital Tract and Plasma
Kemal KS, Burger H, Mayers D, et al
J Infect Dis. 2007 Feb 15;195(4):535-45.
Abstract

Treatment Discontinuation/Interruption

Journal Papers, Abstracts, and Commentaries

Factors and Temporal Trends Associated With Highly Active Antiretroviral Therapy
Discontinuation in the Women's Interagency HIV Study.
Ahdieh-Grant L, Tarwater PM, Schneider MF, et al
J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):500-503.
Abstract

Adverse Events

Journal Papers, Abstracts, and Commentaries

Changes in Body Mass Index Following HAART Initiation among HIV-Infected Women in the Women's Interagency HIV Study.
Sharma A, Bynum SA, Schneider MF, et al
J AIDS Clin Res. 2014;5.
Abstract

The Impact of Kidney Function at Highly Active Antiretroviral Therapy Initiation on Mortality in
HIV-Infected Women.
Estrella MM, Parekh RS, Abraham A, et al
J Acquir Immune Defic Syndr. 2010 Jun 25
Abstract

Effect of Non-Nucleoside Reverse Transcriptase Inhibitors on Cytokine, Chemokine,
and Immunoglobulin Profiles in Serum and Genital Secretions of HIV-Infected Women.
Sachdeva RK, Wanchu A, Bagga R, Malla N, Sharma M.
J Interferon Cytokine Res. 2010 Feb 28
Abstract

Diagnostics/Monitoring

Journal Papers, Abstracts, and Commentaries

Post-use assay of vaginal rings (VRs) as a potential measure of clinical trial adherence.
Spence P, Nel A, van Niekerk N, et al
J Pharm Biomed Anal. 2016 Mar 14;125:94-100.
Abstract

FULL-TEXT ARTICLE
Determination of HIV-1 coreceptor tropism using provira DNA in women before and after viral suppression.
Baumann RE, Rogers AA, Hamdan HB, et al
AIDS Res Ther. 2015 Apr 18;12:11
Paper

Cheminformatics Analysis to Identify Predictors of Antiviral Drug Penetration into the Female Genital Tract.
Thompson C, Sedykh A, Nicol M, et al
AIDS Res Hum Retroviruses. 2014
Abstract

Women abd HIV Main Page

Main New and Noteworthy

Home Page

HIV Clinical Management